Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors: A Multicenter Open-label Single-arm Phase I Trial

Trial Profile

TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors: A Multicenter Open-label Single-arm Phase I Trial

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Nov 2018

At a glance

  • Drugs Doxorubicin liposomal (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 12 Nov 2018 According to the InnoMedica media release, the Swissmedic has approved this trial. The Graubunden Cantonal Hospital was officially opened as the second study centre and recruitment is ongoing at this centre.
    • 06 Sep 2018 Status changed from not yet recruiting to recruiting.
    • 04 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top